Neogenomics (NEO) Enterprise Value (2016 - 2025)
Neogenomics (NEO) has disclosed Enterprise Value for 16 consecutive years, with -$164.1 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Enterprise Value rose 57.68% year-over-year to -$164.1 million, compared with a TTM value of -$164.1 million through Sep 2025, up 57.68%, and an annual FY2024 reading of -$386.8 million, up 6.83% over the prior year.
- Enterprise Value was -$164.1 million for Q3 2025 at Neogenomics, down from -$154.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$154.7 million in Q2 2025 and bottomed at -$612.0 million in Q1 2021.
- Average Enterprise Value over 5 years is -$359.9 million, with a median of -$355.1 million recorded in 2024.
- The sharpest move saw Enterprise Value plummeted 609.5% in 2021, then skyrocketed 57.68% in 2025.
- Year by year, Enterprise Value stood at -$515.4 million in 2021, then rose by 15.02% to -$438.0 million in 2022, then rose by 5.2% to -$415.2 million in 2023, then grew by 6.83% to -$386.8 million in 2024, then skyrocketed by 57.58% to -$164.1 million in 2025.
- Business Quant data shows Enterprise Value for NEO at -$164.1 million in Q3 2025, -$154.7 million in Q2 2025, and -$346.2 million in Q1 2025.